NAV
Explore a selection of essential drug information below, or:
Unlock enhanced features & extensive drug insights. Create a free account.
Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

TD-0903

Explore a selection of our essential drug information below, or:

CREATE FREE ACCOUNT
Full Drug Profiles
Unlock enhanced features & extensive drug insights, including detailed interaction data & regulatory status. Create a free account.
SUBSCRIBERECOMMENDED FOR PHARMA
Data Packages
Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

Identification

Generic Name
TD-0903
DrugBank Accession Number
DB16463
Background

TD-0903 was investigated in clinical trials for its potential to treat acute lung injury (ALI) associated with COVID-19, including NCT04350736, NCT05091723 (a pharmacokinetics study in healthy participants with supplemental oxygenation), and NCT04402866 (focused on ALI and lung inflammation associated with COVID-19)

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 527.673
Monoisotopic: 527.300873459
Chemical Formula
C30H37N7O2
Synonyms
  • (3-(DIMETHYLAMINO)AZETIDIN-1-YL)((6S)-2-(6-(2-ETHYL-4-HYDROXYPHENYL)-1H-INDAZOL-3-YL)-5-(PROPAN-2-YL)-4,5,6,7-TETRAHYDRO-1H-IMIDAZO(4,5-C)PYRIDIN-6-YL)METHANONE
  • (S)-(3-(DIMETHYLAMINO)AZETIDIN-1-YL)(2-(6-(2-ETHYL-4-HYDROXYPHENYL)-1H-INDAZOL-3-YL)-5-ISOPROPYL-4,5,6,7-TETRAHYDRO-3H-IMIDAZO(4,5-C)PYRIDIN-6-YL)METHANONE
  • METHANONE, (3-(DIMETHYLAMINO)-1-AZETIDINYL)((6S)-2-(6-(2-ETHYL-4-HYDROXYPHENYL)-1H-INDAZOL-3-YL)-4,5,6,7-TETRAHYDRO-5-(1-METHYLETHYL)-3H-IMIDAZO(4,5-C)PYRIDIN-6-YL)-
  • NEZULCITINIB
External IDs
  • TD-0903
  • THRX-136377
Unlock the secrets to drugging the undruggable
Discover how groundbreaking research is turning "undruggable" targets into therapeutic opportunities.
Download eBook
Unlock the secrets to drugging the undruggable
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

TD-0903 is a nebulized inhalation solution that inhibits janus kinase and selectively targets the lungs. This inhibition of JAK-STAT signalling aims to reduce complications associated with cytokine challenges in the airways. The anti-inflammatory mechanism associated with TD-0903 may reduce hyperinflammation in patients experiencing acute respiratory distress syndrome (ARDS).

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
CXA4I8AH6A
CAS number
2412496-23-0
InChI Key
VQIIUJSNIKEMCK-MHZLTWQESA-N
InChI
InChI=1S/C30H37N7O2/c1-6-18-11-21(38)8-10-22(18)19-7-9-23-24(12-19)33-34-28(23)29-31-25-13-27(37(17(2)3)16-26(25)32-29)30(39)36-14-20(15-36)35(4)5/h7-12,17,20,27,38H,6,13-16H2,1-5H3,(H,31,32)(H,33,34)/t27-/m0/s1
IUPAC Name
SMILES
CCC1=C(C=CC(O)=C1)C1=CC=C2C(NN=C2C2=NC3=C(C[C@H](N(C3)C(C)C)C(=O)N3CC(C3)N(C)C)N2)=C1

References

General References
  1. External Link [Link]
  2. External Link [Link]
ChemSpider
115009351
ChEMBL
CHEMBL4802163

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
Unlock 175K+ rows when you subscribe.View sample data
2CompletedTreatmentAcute Lung Injury (ALI) Associated With COVID-19 / Coronavirus Disease 2019 (COVID‑19) / Lung Inflammation Associated With COVID-191somestatusstop reasonjust information to hide
1CompletedTreatmentAcute Lung Injury (ALI) Associated With COVID-19 / Coronavirus Disease 2019 (COVID‑19) / Inflammatory Lung Conditions Associated With COVID-191somestatusstop reasonjust information to hide
1CompletedTreatmentAcute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at January 21, 2021 01:43 / Updated at July 24, 2024 23:35